Analysts await Inovio Pharmaceuticals, Inc. (NASDAQ:INO) to report earnings on May, 09 for the fiscal quarter ending Mar 2016.

They expect $-0.23 EPS, down 21.74% or $0.05 from last year’s $-0.18 per share.

At the moment 5 analysts are watching Inovio Pharmaceuticals, Inc. (NASDAQ:INO), 2 rate it “Buy”, 3 “Outperform”, 0 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Jun-16, 3 analysts have a mean sales target of 4.92 million. For the quarter ending Sep-16, 3 analysts have a mean sales target of 4.61 million whilst for the year ending Dec-16, 5 analysts have a mean target of 34.53 million.

In terms of earnings per share, 4 analysts have a -0.06 EPS mean target for the quarter ending Jun-16, for the quarter ending Sep-16, 4 analysts have a -0.09 EPS mean target and for the quarter ending Sep-16 there are 5 estimates of -0.69 EPS.

The biggest institutional shareholders in Inovio Pharmaceuticals, Inc. include BlackRock Fund Advisors which owns 3 million shares in the company valued at $18.59 million. Vanguard Group Inc is the second biggest holder with 2 million shares currently valued at 16.67 million whilst State Street Corp has 2 million shares valued at 16.42 million.

Total shares held by institutions as of the most recent company filings are 21,591,230 with a reported 1,213,583 bought and 3,501,753 sold. These holdings make up 29.89% of the company’s outstanding shares.

Currently insiders hold 4,460,271 shares in the business which makes up 6.18% of shares. The biggest holder currently is Kim Jong Joseph who owns 1,806,972 shares (2.50% of those outstanding), whilst Tee Khiang Ng holds 1,113,923 (1.54% of shares outstanding) and Kevin Rassas holds 726,088 (1.01% of shares outstanding).

The stock decreased 1.32% or $0.12 during the last trading session, hitting $9.24. Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has risen 24.03% over the past 6 months and is uptrending.